What is claimed is:

1. A recombinant Herpes Simplex oncolytic virus comprising a mammalian PTEN-Long gene.

2. The recombinant virus of claim 1, wherein the virus has been modified to target tumor cells.

3. The recombinant virus of claim 1 or 2, wherein the virus has been modified to place genes critical to viral replication under the control of a tumor-specific promoter.

4. The recombinant virus of any one of claims 1 to 3, wherein the recombinant virus comprises a Herpes Simplex Virus- 1 backbone.

5. The recombinant virus of claim 4, wherein the virus is HSVQuick (HSVQ).

6. The recombinant virus of any one of claims 1 to 5, wherein the PTEN-Long gene is operatively linked to a tissue specific promoter.

7. The recombinant virus of claim 6, which is HSV P10 (RAPTOR).

8. The recombinant virus of any one of claims 1 to 7, wherein the PTEN-Long gene is operatively linked to an inducible promoter.

9. The recombinant virus of any one of claims 1 to 7, wherein the PTEN-Long gene is operatively linked to a constitutive promoter.

10. Use of a recombinant virus of any one of claims 1 to 9 for the manufacture of a medicament for the treatment of a cancer in a subject.

11. Use of a recombinant virus of any one of claims 1 to 9 for the manufacture of a medicament for inhibiting PD-Ll in a cancer cell in a subject.

12. Use of a recombinant virus of any one of claims 1 to 9 for the manufacture of a medicament for increasing the number of infiltrating CD8 T cells or Natural Killer cells at the site of a cancer in a subject.

13. Use of a recombinant virus of any one of claims 1 to 9 for the manufacture of a medicament for inhibiting the metastasis of a cancer in a subject.

14. An *ex-vivo* method of inhibiting PD-L1 in a cancer cell comprising contacting the

cancer cell with the recombinant virus of any one of claims 1 to 9.